Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ADMA BiologicsADMA -1.19%64 3-1 Month Momentum % is -22.74% as of Jul. 26, 2026. GuruFocus rates ADMA with a GF Score™ of 64/100 and a GF Value™ of $18.16 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 1,395 Biotechnology companies, ADMA Biologics ranks worse than 71.11% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-07-26), ADMA Biologics's 3-1 Month Momentum % is -22.74%.
The industry rank for ADMA Biologics's 3-1 Month Momentum % or its related term are showing as below:
ADMA's 3-1 Month Momentum % is ranked worse than 71.11% of 1395
companies
in the Biotechnology industry
Industry Median: -10.71
vs ADMA: -22.74
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
ADMA Biologics 3-1 Month Momentum % Related Terms
ADMA vs ZLAB, HRMY, STOK: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, ADMA Biologics's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ADMA Biologics 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ADMA Biologics's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where ADMA Biologics's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ADMA Biologics (ADMA) has a 3-1 Month Momentum % of -22.74% as of Jul. 26, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on ADMA Biologics and its competitors. According to the industry distribution chart, ADMA Biologics ranks #992 out of 1395 companies in the Biotechnology industry, placing it in the top 71.1%.
Is ADMA Biologics' 3-1 Month Momentum % too high?
ADMA Biologics' current 3-1 Month Momentum % is -22.74%. Based on the distribution chart, ADMA Biologics ranks #992 out of 1395 companies in the Biotechnology industry, which is below the industry midpoint. Overall, ADMA Biologics has a GF Score™ of 64/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ADMA Biologics' 3-1 Month Momentum % compare to ZLAB and HRMY?
According to the Biotechnology industry distribution chart, ADMA Biologics ranks #992 out of 1395 companies for 3-1 Month Momentum %. This places ADMA Biologics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on ADMA Biologics and its competitors. ADMA Biologics's current 3-1 Month Momentum % is -22.74%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ADMA Biologics stock overvalued right now?
Based on GuruFocus' analysis, ADMA Biologics (ADMA) is currently considered Significantly Undervalued. The stock's GF Value™ is $18.16, compared to a current price of $8.28 — trading 54.4% below its estimated fair value. The current 3-1 Month Momentum % is -22.74%. ADMA Biologics' overall GF Score™ is 64/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For ADMA Biologics (ADMA), the current 3-1 Month Momentum % is -22.74% as of Jul. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ADMA Biologics (ADMA) Overvalued in 2026?
Based on GuruFocus' analysis, ADMA Biologics stock appears to be undervalued.
The current stock price of $8.28 is trading 54.4% below its estimated GF Value™ of $18.16.
GuruFocus considers ADMA Biologics to be Significantly Undervalued.
Key valuation signals for ADMA:
3-1 Month Momentum %: -22.74%
GF Value™: $18.16 vs. price of $8.28 (54.4% below fair value)
No single metric tells the full story. See the ADMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.
64GF Score
Get the complete analysis for ADMA
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ADMA has been successfully added to your 
